Answers are grounded in this paper and cite their sources.
Retrospective study reveals transfusion requirements affect survival in severe aplastic anemia patients post-HSCT, suggesting lower needs improve outcomes.
Background: Severe Aplastic Anemia (SAA) is well recognized life threatening hematological disorder characterized by pancytopenia with hyopcellular marrow without evidence of malignant infiltration or fibrotic changes. Objective: The goal of this research was to assess the effects of the pre- and post-transplant transfusion requirements on the outcomes of SAA patients who underwent HSCT. Study Design: This is a retrospective design study. Duration and Place of the study: This study was conducted at Gambat Institute of Medical Sciences specializing in hematology and BMT, between 1st, December 2018 to 2nd, January 2023. Material and Methods: Total Patients were 84, in which 45 patients were diagnosed with SAA who have undergone HSCT. Data were extracted regarding demographic features, transfusion history, transplant outcomes, and post-transplant complications. Patients were categorized into two groups: Group A (≤20 transfusions) and Group B (>20 transfusions). The diagnosis of Severe Aplastic Anemia is made using recognized criteria, which include a bone marrow cellularity of less than 25%, and the presence of at least two of the following: an absolute neutrophil count of less than 500/µL, a platelet count of less than 20,000/µL, or a reticulocyte count of less than 20,000/µL. Results: The study group consisted of individuals aged 4 to 41 years, with a higher proportion of males, having a male-to-female ratio of 1.2:1. Majority of the patients had a sibling donor (97.8%) while fewer had unrelated (2.2%) donor. Group A demonstrated superior outcomes with a 5-year overall survival of 84.0% compared to 60.0% in Group B (p=0.02). Graft failure (4.0% vs. 20.0%, p=0.03), severe infections (12.0% vs. 30.0%, p=0.01), iron overload (8.0% vs. 25.0%, p=0.04), and alloimmunization (12.0% vs. 30.0%, p=0.03) were significantly lower in Group A. Conclusion: Transfusion burden before and after HSCT is strongly associated with adverse outcomes in SAA patients. Strategies to minimize transfusion dependency may improve transplant success and survival.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: